DDInter381 DDInter1435
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Cinacalcet {u} (Compound) resembles {v} (Compound) Floctafenine
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Cinacalcet {u} (Compound) binds {v} (Gene) CASR
Cinacalcet {u} (Compound) palliates {v} (Disease) chronic kidney failure
Cinacalcet {u} (Compound) is included by {v} (Pharmacologic Class) Increased Calcium-sensing Receptor Sensitivity
Cinacalcet {u} (Compound) causes {v} (Side Effect) Dyspepsia
Cinacalcet (Compound) resembles Floctafenine (Compound)
Cinacalcet (Compound) resembles Duloxetine (Compound)
Cinacalcet (Compound) binds CASR (Gene)
Cinacalcet (Compound) palliates chronic kidney failure (Disease)
Cinacalcet (Compound) is included by Increased Calcium-sensing Receptor Sensitivity (Pharmacologic Class)
Cinacalcet (Compound) causes Dyspepsia (Side Effect)